



<http://researchspace.auckland.ac.nz>

### *ResearchSpace@Auckland*

#### **Copyright Statement**

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

#### **General copyright and disclaimer**

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

*THE ROLE OF TOPOISOMERASE II IN  
AMSACRINE RESISTANCE*

*SANDRA J. RATTRAY (née DARKIN)*

*Department of Cellular and Molecular Biology*

*University of Auckland.*

*A thesis submitted in fulfilment of the requirements  
for the Degree of Doctor of Philosophy.*

*May, 1989.*

*FRONTISPIECE*

*There is no end, indeed, to making books or experiments, or, to travel, or to gathering wealth. Problem gives rise to problem. We may study for ever, and we are never as learned as we would. We have never made a statue worthy of our dreams. And when we have discovered a continent, or crossed a chain of mountains, it is only to find another ocean or another plain upon the farther side. In the infinite universe there is room for our swiftest diligence and to spare. It is not like the works of Carlyle, which can be read to an end. Even in a corner of it, in a private park, or in the neighbourhood of a single hamlet, the weather and the seasons keep so deftly changing that although we walk there for a lifetime there will be always something to startle and delight us.*

*Robert Louis Stevenson  
(out of El dorado)*

## ABSTRACT

1. Antitumour agents from many different chemical classes including acridines, have been shown to induce topoisomerase II-associated DNA breaks both in cultured mammalian cells and *in vitro* in the presence of purified mammalian DNA topoisomerase II. However, mechanisms linking these protein-associated DNA breaks with drug cytotoxicity are poorly understood. Whether this type of DNA damage is responsible for drug cytotoxicity was investigated using a number of acridine derivatives belonging to the same chemical class but with varying potency *in vivo*. The modulation of topoisomerase II-mediated DNA breaks in whole L1210 cells, isolated nuclei and nuclear extract systems correlated with drug-induced cytotoxicity, at least for the drugs belonging to the amsacrine lineage. In contrast, there was no direct relationship between the inhibition of topoisomerase II strand-passing activity and the cytotoxic action of topoisomerase II-specific anticancer drugs.

It was concluded that drug-induced formation and stabilization of the topoisomerase II-DNA cleavable complex, rather than inhibition of its formation or of strand-passing functions, is responsible for DNA strand breakage and cell death caused by antitumour acridines such as amsacrine.

2. Two tissue culture systems (CHO-AA8 cells or P815 cell cycle mutants) were used as models to study the involvement of topoisomerase II in the resistance of non-cycling cells to amsacrine.

Plateau-phase CHO-AA8 cells with a G<sub>0</sub>/G<sub>1</sub> DNA content are resistant to amsacrine and contain fewer DNA breaks than log-phase cells after drug treatment (Robbie *et al.*, 1988). The observations of Robbie *et al.* (1988) were further investigated in this thesis. The phage P4 DNA

unknotting activity in CHO-AA8 cell nuclear extracts decreased 2-fold when the cells entered plateau-phase, but there was no difference in the sensitivity of unknotting to amsacrine between log- and plateau-phase nuclear extracts. Furthermore, drug stimulation of protein-DNA complex formation was similar in whole cells, isolated nuclei and nuclear extracts from either log- or plateau-phase cells. However, stimulation of complex formation in cells, nuclei or nuclear extracts was approximately 4-fold lower in plateau-phase than in log-phase. These results suggested that drug-enzyme interaction was altered in plateau-phase and there was a good correlation between the proliferative state of cells, amsacrine sensitivity, DNA breakage and topoisomerase II-DNA complex formation.

The second system used to study the effect of amsacrine was the cold-sensitive (proliferating at 39.5°C; reversibly arrested in G1-phase at 33°C) cell-cycle mutant 21-Fb of the murine mastocytoma cell line, P815. The sensitivity of arrested 21-FB cells to amsacrine decreased less than two-fold in cell survival experiments when compared to proliferating cells. In contrast, DNA breakage and stimulation of protein-DNA complex formation in intact cells, lysed cells or isolated nuclei was reduced approximately 10-fold in amsacrine-treated arrested cells and DNA-topoisomerase II activity in arrested cells was only 5 % of the activity in proliferating cells. Thus in contrast to the CHO-AA8 cell system, there was no correlation between cell survival and DNA damage or DNA topoisomerase II activity in drug treated 21-Fb cells.

The exact reasons for the differences in amsacrine sensitivity in growth arrested CHO and 21-Fb cells were not resolved. However, it was concluded that a complex relationship exists between amsacrine-induced DNA breakage, topoisomerase II-DNA complex formation, topoisomerase activity and drug cytotoxicity. Moreover, a very complex set of parameters can

influence drug-induced topoisomerase II-mediated lesions and cytotoxicity in different cells or even a single type of cell under different growth conditions.

3. Extracts of K21 murine mastocytoma cells were found to contain a factor that enhances formation of amsacrine-induced topoisomerase II-DNA complexes (PDC) when added to isolated K21 nuclei. The PDC enhancing activity was reduced in extracts from 2 or 6 h cycloheximide- or cordycepin-treated cells, implying that continuous protein synthesis is required to maintain the factor. Preliminary characterization showed that the factor was heat labile and proteinase-sensitive suggesting the factor was a labile protein which was distinct from the two known classes of topoisomerase.

The protein factor was present in at least four other cell lines and was substantially reduced in cells induced into a G1 state by temperature arrest or serum deprivation. Human Jurkat cells selected for resistance to amsacrine and displaying cross-resistance to other topoisomerase II-targeted drugs also exhibited significantly reduced PDC enhancing activity. These results suggested a contributing role for the PDC enhancing factor in mediation of drug resistance.

Fractionation of mouse mastocytoma cell cytoplasmic extracts by salt precipitation, DEAE-cellulose chromatography and SDS-PAGE resulted in a 3571-fold purification of the PDC enhancing activity. The PDC enhancing activity was shown to reside in a 70 kDa protein kinase with specificity for a casein kinase II substrate and sensitive to heparin and anti-casein kinase II antiserum.

This appears to be the first direct evidence of a protein factor that modulates amsacrine induced topoisomerase II action possibly by

*phosphorylating topoisomerase II or proteins associated with topoisomerase II.*

### ACKNOWLEDGEMENTS

I gratefully acknowledge the Auckland Medical Research Foundation for financial support during the course of this study.

I would like to express sincere thanks to Professor Ray Ralph for his diligent supervision of this thesis and for the enthusiastic interest he has shown in all aspects of my research over the past 6 years. I would also like to express special thanks to Dr. Erasmus Schneider for his valuable comments on various aspects of this work and for collaborative studies.

Thanks also must be conveyed to other participants in collaborative studies, specifically Associate-Professor Bruce Baguley, Drs Graeme Finlay, Bill Wilson and Maxine Robbie (The Cancer Research Laboratory and Department of Pathology, Auckland School of Medicine).

To all those who have willingly shared their expertise I give my thanks, particularly to Philip Schofield and Terry Gruijters for their assistance with photography and to Stan Wojick for technical assistance willingly provided whenever required.

To other members of the Department of Cellular and Molecular Biology I probably should thank but appear to have neglected - I haven't, thanks for providing a friendly working environment.

I would like to thank my family, especially Jim and Thelma, for support and encouragement throughout the time I have devoted to this thesis.

To my parents, for their assistance and support in ways too numerous to mention I give my warmest thanks and love.

To my husband, Mark, who though coping with the trials of his own doctorate still found time to type the vast majority of this thesis and to provide general help and encouragement when needed, I give my love and heartfelt thanks, although it is barely sufficient. He above all understands and has shared the costs and rewards of experimental research.



## TABLE OF CONTENTS

	Page No.
Frontispiece	i
Abstract	ii
Acknowledgements	vi
Table of Contents	vii
List of Abbreviations	xiii
CHAPTER ONE: INTRODUCTION	
1.1 Perspectives: Current status of cancer chemotherapy	1
1.2 Development of "broad spectrum" antitumour drugs:- the clinical antitumour drug AMSACRINE and related compounds.	3
1.3 The mechanism of action of amsacrine (and related derivatives.	8
1.3.1 DNA binding	8
1.3.2 DNA breakage	10
1.3.3 Evidence for topoisomerase II-mediated cleavage of DNA	12
1.3.4 Topoisomerase II reactions	13
1.3.5 Effects of amsacrine, other intercalating agents and epipodophyllotoxins on topoisomerase II reactions <u>in vitro</u>	16
1.4 Biological role of topoisomerase II	18
1.4.1 Cellular regulation of topoisomerase II	26
1.5 The question of toxicity: Possible mechanisms of cell killing by mammalian topoisomerase II poisons.	27
1.6 Modes of action of anticancer drugs	29

1.7	<i>Aims of this study</i>	34
 <i>CHAPTER TWO: MATERIALS AND GENERAL METHODS</i>		
A	<i>Materials</i>	36
B	<i>General Methods</i>	40
 <i>CHAPTER THREE: CYTOTOXICITY AND DNA BREAKAGE PROPERTIES OF ANTITUMOUR ACRIDINES: ROLE OF DNA TOPOISOMERASE II</i>		
3.1	<i>Introduction</i>	57
3.2	<i>Methods</i>	61
3.3	<i>Results</i>	64
3.3.1	<i><u>In vivo</u> activity of related acridine derivatives against L1210 leukemia</i>	64
3.3.2	<i><u>In vitro</u> growth inhibition by the acridine compounds in continuous exposure assays</i>	66
3.3.3	<i>The effect of related acridine derivatives on DNA strand breakage</i>	66
3.3.4	<i>Stimulation of protein-DNA complex formation by the acridine derivatives</i>	70
3.3.5	<i>Inhibition of topoisomerase II strand-passing activity: The P4 unknotting assay</i>	76
3.4	<i>Discussion</i>	76

## CHAPTER FOUR: THE ROLE OF TOPOISOMERASE II IN AMSACRINE RESISTANCE

4.1	Introduction	81
-----	--------------	----

*Part I: Mechanisms of resistance of non-cycling mammalian cells to amsacrine: The role of DNA topoisomerase II in Log- and Plateau- phase CHO cells*

4.2	Introduction	82
4.3	Methods	83
4.4	Results	86
4.4.1	Quantitation of DNA topoisomerase II strand-passing activity in log- and plateau- phase AA8 cells	86
4.4.2	Inhibition of unknotting activity by amsacrine	88
4.4.3	Stimulation of covalent protein-DNA complex formation in log- and plateau- phase cells by amsacrine	88
4.4.4	<u>In vitro</u> stimulation of covalent DNA topoisomerase II complex formation with nuclear extracts from log- and plateau- phase cells	95
4.5	Part I Summary	95

*Part II: The relationship between sensitivity to amsacrine and DNA topoisomerase II in a cold-sensitive cell cycle mutant of a murine mastocytoma cell line.*

4.6	Introduction	98
4.7	Methods	98
4.8	Results	102
4.8.1	Amsacrine cytotoxicity in proliferating and arrested	102

	<i>21-Fb cells</i>	
4.8.2	<i>Amsacrine-induced DNA breakage</i>	102
4.8.3	<i>Stimulation of protein-DNA complex formation</i>	104
4.8.4	<i>Quantitation of DNA topoisomerase II strand-passing activity</i>	107
4.9	<i>Part II Summary</i>	112
4.10	<i>Discussion</i>	112
4.10.1	<i>The relationship between sensitivity to amsacrine and DNA topoisomerase II in log- and plateau-phase CHO-AA8 cells</i>	114
4.10.2	<i>The relationship between sensitivity to amsacrine and DNA topoisomerase II in a cold sensitive cell-cycle mutant of a murine mastocytoma cell line</i>	116
4.10.3	<i>What is the role of topoisomerase II in cellular drug sensitivity? The CHO-AA8 cell system versus the 21-Fb cell cycle mutant system</i>	118

CHAPTER FIVE: DEVELOPMENT OF A SYSTEM TO QUANTITATE PROTEIN-DNA COMPLEXES IN ISOLATED NUCLEI: EVIDENCE FOR A FACTOR THAT ENHANCES AMSACRINE-INDUCED TOPOISOMERASE II-DNA COMPLEX FORMATION

5.1	<i>Introduction</i>	123
5.2	<i>Methods, Results and Discussion</i>	124
5.2.1	<i>High non-specific protein-DNA complex formation</i>	125
5.2.2	<i>Absence of drug-induced protein-DNA complexes in isolated K21 or L1210 nuclei</i>	129
5.2.3	<i>Preparation of cytoplasmic extracts from K21 cells</i>	139
5.2.4	<i>Preparation of isolated nuclei</i>	139

5.2.5	Quantitation of PDC in nuclei with added cytoplasmic extract	140
5.3	Summary	142

CHAPTER SIX: A PROTEIN FACTOR THAT ENHANCES AMSACRINE MEDIATED FORMATION OF TOPOISOMERASE II-DNA COMPLEXES IN MURINE MASTOCYTOMA CELL NUCLEI: A PRELIMINARY CHARACTERIZATION

6.1	Introduction	144
6.2	Methods	146
6.3	Results	148
6.3.1	Facilitation and characterization of amsacrine-induced PDC formation in isolated nuclei by cytoplasmic extracts	148
6.3.2	The effect of inhibiting protein and RNA synthesis on cytoplasmic PDC enhancing activity	154
6.3.3	Physicochemical characterization of the cytoplasmic PDC enhancing activity	156
6.4	Discussion	160

CHAPTER SEVEN: GENERALITY OF THE PDC ENHANCING FACTOR AND ITS POSSIBLE INVOLVEMENT IN DRUG RESISTANCE

7.1	Introduction	164
7.2	Methods and Results	165
7.2.1	Generality of the PDC enhancing factor	165
7.2.2	The involvement of PDC enhancing activity in drug resistance	167
7.2.2.1	PDC enhancing activity in proliferating (39.5°C) and arrested (33°C) temperature sensitive 21-Fb	168

	<i>cells</i>	
7.2.2.2	<i>PDC enhancing activity in K21 cells arrested with low serum</i>	170
7.2.2.3	<i>PDC enhancing activity in amsacrine sensitive and resistant human Jurkat cells</i>	170
7.3	<i>Discussion</i>	174

CHAPTER EIGHT: ISOLATION AND PRELIMINARY IDENTIFICATION OF THE  
PDC ENHANCING FACTOR

8.1	<i>Introduction</i>	176
8.2	<i>Methods</i>	177
8.3	<i>Results</i>	185
8.3.1	<i>Ammonium sulphate precipitation of cytoplasmic extracts</i>	185
8.3.2	<i>Purification of the PDC enhancing factor by column chromatography</i>	187
8.3.3	<i>Gel electrophoresis of column fractions</i>	190
8.3.4	<i>Elution and renaturation of the 70 kDa protein from SDS-polyacrylamide gels</i>	193
8.3.5	<i>Preliminary identification of the 70 kDa protein with PDC enhancing activity</i>	196
8.3.5.1	<i>Heparin-sensitivity of the PDC enhancing factor</i>	196
8.3.5.2	<i>Sensitivity of the PDC enhancing activity to anti rat-liver casein kinase II antiserum</i>	199
8.3.5.3	<i>Protein kinase activity of the 70 kDa protein</i>	199
8.4	<i>Discussion</i>	201

*CHAPTER NINE: CONCLUDING DISCUSSION*

9.1	<i>The question of cytotoxicity</i>	204
9.2	<i>The role of topoisomerase II in amsacrine resistance</i>	206
9.3	<i>A protein factor that enhances amsacrine mediated formation of topoisomerase II-DNA complexes: Speculations on its role in drug action, drug resistance and cancer cell growth.</i>	211
9.4	<i>General consideration</i>	219
	<i>REFERENCES</i>	220
	<i>APPENDICES A1 - A4: Publications.</i>	

## ABBREVIATIONS

9-AA	9-aminoacridine
ALL	acute lymphoblastic leukemia
$\alpha$ -MEM	alpha modified minimum essential medium
AMSA	4'-(9-acridinylamine)methanesulphonanilide
$[\gamma$ - <sup>32</sup> P]-dATP	deoxyadenoside 5'- $[\gamma$ - <sup>32</sup> P] triphosphate
ATP	adenosine 5'-triphosphate
bisacrylamide	N,N'-methylenebisacrylamide
BSA	bovine serum albumin
cDNA	complementary DNA
CHO	chinese hamster ovary cells
CI-921	N,5'-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamine)-phenylamino]-4-acridine carboxamide.
DAPI	4',6'-diamino-2-phenylindole
dATP	2'-deoxyadenosine 5'-triphosphate
ddH <sub>2</sub> O	double distilled water
dGTP	2'-deoxyguanosine 5'-triphosphate
DMSO	dimethyl sulphoxide
DSB	(DNA) double-strand break
DTT	1,4-dithiothreitol
dTTP	2'-deoxythymidine 5'-triphosphate
EDTA	ethylene diamine tetraacetic acid
EGTA	ethylene glycol bis( $\beta$ -aminoethylether)-N,N'-tetraacetic acid
FADU	fluorescence assay for DNA unwinding
FCS	fetal calf serum
FPLC	fast pressure liquid chromatography
HMG	high mobility group (protein)
HPLC	high pressure liquid chromatography
hsp	heat shock protein
m-AMSA	4'-(9-acridinylamine)methanesulphon-m-anisidide
o-AMSA	4'-(9-acridinylamine)methanesulphon-o-anisidide
PBS	phosphate-buffered saline
PDC	protein-DNA-complex
POPOP	1,4-bis-[2-(5-phenyloxazolyl)] benzene
PPO	2,5-diphenyloxazole
QSAR	quantitative structure-activity relationship
SCE	sister chromatid exchange
SD	standard deviation
SDS	sodium dodecyl sulphate
SE	standard error
TBS	Tris buffered saline
TCA	trichloroacetic acid
TEMED	N,N,N',N'-tetramethylenediamine
Tris	tris(hydroxymethyl)aminomethane